On Invalid Date, Anika Therapeutics (NASDAQ: ANIK) reported Q1 2024 earnings per share (EPS) of -$0.31, up 56.34% year over year. Total Anika Therapeutics earnings for the quarter were -$4.51 million. In the same quarter last year, Anika Therapeutics's earnings per share (EPS) was -$0.71.
As of Q2 2024, Anika Therapeutics's earnings has grown year over year. Anika Therapeutics's earnings in the past year totalled -$76.83 million.
What was ANIK's revenue last quarter?
On Invalid Date, Anika Therapeutics (NASDAQ: ANIK) reported Q1 2024 revenue of $40.52 million up 6.85% year over year. In the same quarter last year, Anika Therapeutics's revenue was $37.92 million.
What was ANIK's revenue growth in the past year?
As of Q2 2024, Anika Therapeutics's revenue has grown 7.49% year over year. This is 3.2 percentage points lower than the US Medical Devices industry revenue growth rate of 10.69%. Anika Therapeutics's revenue in the past year totalled $169.26 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.